In conclusion, by exploring the clinical and biological correlates of DLL3 expression, we reveal the expanded utility of DLL3-targeted therapies across diverse neuroendocrine and non-neuroendocrine cancers. The gene discussed is DLL3; the disease is neuroendocrine carcinoma.